$29.64
Insights on Evolent Health, Inc. - Class A Shares
Revenue is up for the last 12 quarters, 215.07M → 556.05M (in $), with an average increase of 8.2% per quarter
Netprofit is down for the last 2 quarters, -25.32M → -33.41M (in $), with an average decrease of 31.9% per quarter
In the last 1 year, Healthequity Inc has given 36.6% return, outperforming this stock by 47.8%
0.98%
Downside
Day's Volatility :2.96%
Upside
2.0%
21.29%
Downside
52 Weeks Volatility :36.43%
Upside
19.24%
Period | Evolent Health, Inc. - Class A Shares | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -1.28% | -0.5% | 0.0% |
6 Months | 6.65% | 5.9% | 0.0% |
1 Year | -11.16% | 3.1% | -1.9% |
3 Years | 52.63% | 14.2% | -21.8% |
Market Capitalization | 3.5B |
Book Value | $9.38 |
Earnings Per Share (EPS) | -1.28 |
PEG Ratio | -1.37 |
Wall Street Target Price | 44.67 |
Profit Margin | -5.76% |
Operating Margin TTM | 1.23% |
Return On Assets TTM | 0.86% |
Return On Equity TTM | -10.74% |
Revenue TTM | 2.0B |
Revenue Per Share TTM | 17.65 |
Quarterly Revenue Growth YOY | 45.4% |
Gross Profit TTM | 316.6M |
EBITDA | 127.5M |
Diluted Eps TTM | -1.28 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | 1.16 |
EPS Estimate Next Year | 1.63 |
EPS Estimate Current Quarter | 0.15 |
EPS Estimate Next Quarter | 0.21 |
What analysts predicted
Upside of 50.71%
FY18 | Y/Y Change | |
---|---|---|
Revenue | 627.1M | ↑ 44.17% |
Net Income | -52.7M | ↓ 13.2% |
Net Profit Margin | -8.4% | ↑ 5.55% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 846.4M | ↑ 34.98% |
Net Income | -305.6M | ↑ 480.31% |
Net Profit Margin | -36.1% | ↓ 27.7% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.0B | ↑ 20.8% |
Net Income | -334.2M | ↑ 9.38% |
Net Profit Margin | -32.69% | ↑ 3.41% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 908.0M | ↓ 11.2% |
Net Income | -30.3M | ↓ 90.94% |
Net Profit Margin | -3.34% | ↑ 29.35% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.4B | ↑ 48.91% |
Net Income | -18.7M | ↓ 38.25% |
Net Profit Margin | -1.38% | ↑ 1.96% |
FY23 | Y/Y Change | |
---|---|---|
Revenue | 2.0B | ↑ 45.26% |
Net Income | -113.0M | ↑ 504.46% |
Net Profit Margin | -5.76% | ↓ 4.38% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 352.6M | ↑ 10.2% |
Net Income | 2.1M | ↓ 151.47% |
Net Profit Margin | 0.6% | ↑ 1.89% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 382.4M | ↑ 8.47% |
Net Income | -11.3M | ↓ 634.57% |
Net Profit Margin | -2.97% | ↓ 3.57% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 427.7M | ↑ 11.83% |
Net Income | -20.0M | ↑ 76.07% |
Net Profit Margin | -4.67% | ↓ 1.7% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 469.1M | ↑ 9.69% |
Net Income | -34.3M | ↑ 71.77% |
Net Profit Margin | -7.32% | ↓ 2.65% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Revenue | 511.0M | ↑ 8.93% |
Net Income | -25.3M | ↓ 26.22% |
Net Profit Margin | -4.96% | ↑ 2.36% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Revenue | 556.1M | ↑ 8.81% |
Net Income | -33.4M | ↑ 31.93% |
Net Profit Margin | -6.01% | ↓ 1.05% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 1.7B | ↑ 31.2% |
Total Liabilities | 532.9M | ↑ 100.05% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 1.5B | ↓ 13.02% |
Total Liabilities | 569.0M | ↑ 6.76% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↓ 8.53% |
Total Liabilities | 750.6M | ↑ 31.92% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 1.4B | ↑ 3.6% |
Total Liabilities | 725.8M | ↓ 3.3% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 1.8B | ↑ 28.03% |
Total Liabilities | 957.9M | ↑ 31.97% |
FY23 | Y/Y Change | |
---|---|---|
Total Assets | 2.7B | ↑ 47.49% |
Total Liabilities | 1.6B | ↑ 68.35% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 34.92% |
Total Liabilities | 903.0M | ↑ 30.72% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 1.8B | ↑ 3.3% |
Total Liabilities | 957.9M | ↑ 6.07% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 42.49% |
Total Liabilities | 1.5B | ↑ 53.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.6B | ↑ 2.22% |
Total Liabilities | 1.6B | ↑ 5.85% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↑ 0.86% |
Total Liabilities | 1.6B | ↑ 1.28% |
Q4 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 2.7B | ↑ 0.4% |
Total Liabilities | 1.6B | ↑ 2.48% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.7M | ↓ 26.14% |
Investing Cash Flow | -160.4M | ↑ 1207.58% |
Financing Cash Flow | 274.0M | ↑ 65.52% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -42.6M | ↑ 106.5% |
Investing Cash Flow | -181.6M | ↑ 13.26% |
Financing Cash Flow | -35.5M | ↓ 112.97% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -16.2M | ↓ 61.95% |
Investing Cash Flow | 261.1M | ↓ 243.74% |
Financing Cash Flow | -11.9M | ↓ 66.63% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | 38.7M | ↓ 338.81% |
Investing Cash Flow | -15.8M | ↓ 106.05% |
Financing Cash Flow | -29.5M | ↑ 149.1% |
FY22 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -11.6M | ↓ 129.82% |
Investing Cash Flow | -259.1M | ↑ 1541.42% |
Financing Cash Flow | 131.5M | ↓ 545.18% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -3.5M | ↓ 125.4% |
Investing Cash Flow | -255.0M | ↑ 1451.41% |
Financing Cash Flow | 173.1M | ↑ 736.54% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 35.7M | ↓ 1128.67% |
Investing Cash Flow | -4.5M | ↓ 98.25% |
Financing Cash Flow | -10.9M | ↓ 106.27% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.0M | ↓ 122.34% |
Investing Cash Flow | -395.0M | ↑ 8764.3% |
Financing Cash Flow | 379.7M | ↓ 3598.52% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 654.0K | ↓ 108.2% |
Investing Cash Flow | -8.4M | ↓ 97.89% |
Financing Cash Flow | 23.3M | ↓ 93.86% |
Q3 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | 60.5M | ↑ 9153.98% |
Investing Cash Flow | -409.5M | ↑ 4801.75% |
Financing Cash Flow | -37.4M | ↓ 260.17% |
Sell
Neutral
Buy
Evolent Health, Inc. - Class A Shares is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Evolent Health, Inc. - Class A Shares | -6.25% | 6.65% | -11.16% | 52.63% | 137.48% |
Solventum Corp | -10.35% | -10.35% | -10.35% | -10.35% | -10.35% |
Veeva Systems Inc. | -12.28% | -3.64% | 11.92% | -25.89% | 55.54% |
Ge Healthcare Technologies Inc. | -5.22% | 28.56% | 3.82% | 41.97% | 41.97% |
Healthequity Inc | -3.24% | 7.03% | 36.58% | 13.47% | 28.25% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Evolent Health, Inc. - Class A Shares | 712.02 | NA | -1.37 | 1.16 | -0.11 | 0.01 | NA | 9.38 |
Solventum Corp | NA | NA | NA | 0.0 | 0.12 | 0.08 | NA | NA |
Veeva Systems Inc. | 62.42 | 62.42 | 1.35 | 4.76 | 0.13 | 0.05 | NA | 28.8 |
Ge Healthcare Technologies Inc. | 28.36 | 28.36 | 20.11 | 4.3 | 0.19 | 0.06 | 0.0 | 15.67 |
Healthequity Inc | 125.36 | 125.36 | 2.29 | 2.19 | 0.03 | 0.03 | NA | 23.63 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Evolent Health, Inc. - Class A Shares | Buy | $3.5B | 137.48% | 712.02 | -5.76% |
Solventum Corp | NA | $11.7B | -10.35% | NA | 16.42% |
Veeva Systems Inc. | Buy | $32.5B | 55.54% | 62.42 | 22.24% |
Ge Healthcare Technologies Inc. | Buy | $39.3B | 41.97% | 28.36 | 8.02% |
Healthequity Inc | Buy | $6.9B | 28.25% | 125.36 | 5.57% |
FMR Inc
Vanguard Group Inc
BlackRock Inc
Wellington Management Company LLP
JPMorgan Chase & Co
Rock Springs Capital Management LP
our company evolent health supports progressive health care systems lead, build and own the path to value-based care. headquartered in arlington, virginia, we are backed by: the advisory board company (nasdaq: abco), university of pittsburgh medical center health plan, and tpg growth. we integrate the people, processes and technology needed to advance value-based care delivery and innovative payment models. our culture we’ve built a team of dedicated individuals who genuinely enjoy working together. our accessible leadership team cultivates an open-door environment. we take smart risks and when we fail, we fail forward. we respect and encourage commitments outside of work. while we don’t all work the same way or the same hours, we are all dedicated to exceptional results. our benefits treadmill desks, healthy snacks and wellness challenges are just part of our resolve to promote a healthy (and fun!) work environment. we recognize and reward our most valuable asset—our team—wi
Organization | Evolent Health, Inc. - Class A Shares |
Employees | 4700 |
CEO | Mr. Seth Barrie Blackley |
Industry | Miscellaneous Commercial Services |